What had been a sluggish year for North Carolina venture capital picked up considerably last week.
Three deals work nearly $29 million officially closed. Before last week, only seven deals have closed, generating a meager $46.4 million. The 10 deals worth $75 million puts the state a bit ahead of last year’s pace.
Through mid-March 2002, 14 deals worth $60 million had been closed with North Carolina firms.
Targacept in Greensboro led the way with $14 million, an add-on to $46 million rasied as a second round last year.
Stemco closed on $9.8 million.
Network security firm Oculan closed on $5 million.
Here are the 10 deals in the NC list, which will be updated and published each Monday:
Deal size; company; focus; location; investors
1. $24 million; TransTech Pharma; pharmaceutical; High Point, NC; MacAndrews & Forbes, Novo Norodisk A/S, Cephaton
2. $14 million; Targacept; biotech; Nomura International, Oxford Bioscience Partners, JAFCO, Cogene Biotech Ventures, Bison Capital, Rock Castle Ventures; 2nd
3. $9.8 million; Stemco; biotech; Aurora Funds, Intersouth Partners, Becton Dickinson Ventures, Trelys Venture Partners, Tall Oaks Capital.
4. $8.5 million; OrthoNeuro; speciality hospital; Charlotte; New Enterprise Associates.
5. $7 million; Venetica; software; Charlotte; Charles River Ventures, General Catalyst Partners (1st)
6. $5 million; Oculan; networking; Soros Equity Partners.
7. $2 million; Relativity; Cary, NC; software; Wakefield Group, Noro-Moseley
8. $1.6 million; RSS Solutions; software; Greenville; Edgestone Capital Partners.
9. $1.5 million; LiveWire Logic; Morrisville, NC; software and services; Research Triangle Ventures, Gray Ventures
10. $1.3 million; Tranzyme; RTP; biotech; Research Triangle Ventures, Paradigm Venture Partners, Green & Associates. Pacific Rim Ventures